Key clinical point: Sodium-glucose cotransporter 2 (SGLT2) inhibitor therapy confers protection from heart failure to patients with type 2 diabetes regardless of their baseline left ventricular ejection fraction (LVEF).
Major finding: Compared with other glucose-lowering drugs, SGLT2 inhibitor therapy was associated with a 47% reduction in all-cause mortality in patients with preserved LVEF and a 62% reduction in patients with reduced LVEF.
Study details: This observational study involved a comparison of outcomes in 5,307 patients with type 2 diabetes placed on an SGLT2 inhibitor and an equal number of propensity-matched patients started on other glucose-lowering medications.
Disclosures: The study presenter reported serving as a consultant to roughly a dozen pharmaceutical companies.
Kosiborod M. ACC 19, Abstract #1024-07.